Esketamine performs well when it is administered intravenously. At a dosage of 0.4 mg/kg — average of 31.2mg per participant — it provided a 13.4-point reduction of symptoms according to the 60-point MADRS after 3 days. The result was significant at (p ≥ 0.009). Placebo only reached a reduction of 3-points.

There is currently only one trial of Arketamine in progress however an open label pilot study saw a 20.3-point reduction of symptoms on the MADRS after 3 days. There are many confounders; the dosage was higher at 0.5mg/kg — average of 36.7mg per participant — as it was only a pilot study there was no placebo group and there were only 7 participants, all of which were female. However result was significant at (p ≥ 0.001).

Arketamine is currently entering Phase II clinical trials for treatment-resistant depression. Market will end after Phase III trial data is released and compared with Esketamine efficacy.

Esketamine Trials:

• https://www.biologicalpsychiatryjournal.com/article/S0006-3223(15)00914-2/pdf
  

Arketamine Trials:

• https://clinicaltrials.gov/ct2/show/NCT05414422

• https://sci-hub.se/https://link.springer.com/article/10.1007/s00406-020-01110-5

Apr 17, 6:25pm: Which enantiomer of Ketamine will provide a greater anti-depressant effect? → Will Arketamine promote a greater anti-depressant effect than Esketamine?